The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Advisory Committee Tracker: FDA’s Busy September Extends Beyond Panel Meetings Aug. 28, 2014
- House 21st Century Cures Resource Guide: Key Themes To Watch As Listening Phase Draws To A Close Aug. 27, 2014
- Generic Drug GDUFA Deadlines for Responses To Sponsors Will Not Apply to Some Requests: BE Guidances; Citizen Petitions Aug. 26, 2014
See More Research Notes